These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. New technologies toward dendritic cell-based cancer immunotherapies. Matsue H; Morita A; Matsue K; Takashima A J Dermatol; 1999 Nov; 26(11):757-63. PubMed ID: 10635619 [TBL] [Abstract][Full Text] [Related]
23. Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination. Wei FQ; Sun W; Wong TS; Gao W; Wen YH; Wei JW; Wei Y; Wen WP J Exp Clin Cancer Res; 2016 Jan; 35():18. PubMed ID: 26795730 [TBL] [Abstract][Full Text] [Related]
25. [Dendritic cells and immune function in cancer]. Chaux P Pathol Biol (Paris); 1995 Dec; 43(10):897-903. PubMed ID: 8786896 [TBL] [Abstract][Full Text] [Related]
26. Dendritic cells from bench to bedside and back. Adema GJ Immunol Lett; 2009 Feb; 122(2):128-30. PubMed ID: 19121337 [TBL] [Abstract][Full Text] [Related]
27. [Dendritic cell-based immunotherapy for multiple myeloma -- review]. Zhu XJ; He L; Sun XM Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):821-5. PubMed ID: 19549416 [TBL] [Abstract][Full Text] [Related]
28. Antigen-Loaded Upconversion Nanoparticles for Dendritic Cell Stimulation, Tracking, and Vaccination in Dendritic Cell-Based Immunotherapy. Xiang J; Xu L; Gong H; Zhu W; Wang C; Xu J; Feng L; Cheng L; Peng R; Liu Z ACS Nano; 2015 Jun; 9(6):6401-11. PubMed ID: 26028363 [TBL] [Abstract][Full Text] [Related]
29. Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells. Breckpot K; Heirman C; Neyns B; Thielemans K J Gene Med; 2004 Nov; 6(11):1175-88. PubMed ID: 15468193 [TBL] [Abstract][Full Text] [Related]
31. Proteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy. González FE; Chernobrovkin A; Pereda C; García-Salum T; Tittarelli A; López MN; Salazar-Onfray F; Zubarev RA J Immunol Res; 2018; 2018():3982942. PubMed ID: 29744371 [TBL] [Abstract][Full Text] [Related]
32. Dendritic-tumor cell hybrids induce tumor-specific immune responses more effectively than the simple mixture of dendritic and tumor cells. Pinho MP; Sundarasetty BS; Bergami-Santos PC; Steponavicius-Cruz K; Ferreira AK; Stripecke R; Barbuto JA Cytotherapy; 2016 Apr; 18(4):570-80. PubMed ID: 26971685 [TBL] [Abstract][Full Text] [Related]
33. Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. Lesterhuis WJ; De Vries IJ; Schreibelt G; Schuurhuis DH; Aarntzen EH; De Boer A; Scharenborg NM; Van De Rakt M; Hesselink EJ; Figdor CG; Adema GJ; Punt CJ Anticancer Res; 2010 Dec; 30(12):5091-7. PubMed ID: 21187495 [TBL] [Abstract][Full Text] [Related]
34. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Kranz LM; Diken M; Haas H; Kreiter S; Loquai C; Reuter KC; Meng M; Fritz D; Vascotto F; Hefesha H; Grunwitz C; Vormehr M; Hüsemann Y; Selmi A; Kuhn AN; Buck J; Derhovanessian E; Rae R; Attig S; Diekmann J; Jabulowsky RA; Heesch S; Hassel J; Langguth P; Grabbe S; Huber C; Türeci Ö; Sahin U Nature; 2016 Jun; 534(7607):396-401. PubMed ID: 27281205 [TBL] [Abstract][Full Text] [Related]
35. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Klippstein R; Pozo D Nanomedicine; 2010 Aug; 6(4):523-9. PubMed ID: 20085824 [TBL] [Abstract][Full Text] [Related]
36. Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network. Bodey B; Bodey B; Kaiser HE In Vivo; 1997; 11(4):351-70. PubMed ID: 9292303 [TBL] [Abstract][Full Text] [Related]
37. Dendritic Cells and Cancer Immunity. Gardner A; Ruffell B Trends Immunol; 2016 Dec; 37(12):855-865. PubMed ID: 27793569 [TBL] [Abstract][Full Text] [Related]
38. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639 [TBL] [Abstract][Full Text] [Related]
39. Preclinical evaluation of mRNA trimannosylated lipopolyplexes as therapeutic cancer vaccines targeting dendritic cells. Le Moignic A; Malard V; Benvegnu T; Lemiègre L; Berchel M; Jaffrès PA; Baillou C; Delost M; Macedo R; Rochefort J; Lescaille G; Pichon C; Lemoine FM; Midoux P; Mateo V J Control Release; 2018 May; 278():110-121. PubMed ID: 29630987 [TBL] [Abstract][Full Text] [Related]
40. Fusion of CpG-ODN-stimulating dendritic cells with Lewis lung cancer cells can enhance anti-tumor immune responses. Du YC; Lin P; Zhang J; Lu YR; Ning QZ; Wang Q Tissue Antigens; 2006 May; 67(5):368-76. PubMed ID: 16671943 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]